We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Novo Nordisk A/S
Health Care · Pharmaceuticals
Pure-play on the GLP-1 obesity TAM with the deepest dataset in the class. Ozempic + Wegovy combined run-rate sits near $40B; SELECT cardiovascular outcomes trial unlocked broad payer coverage and Medicare Part D access for cardio-risk reduction.
Pipeline anchors on CagriSema (cagrilintide + semaglutide) and oral semaglutide reformulations, both targeting next-gen efficacy parity with $LLY tirzepatide/retatrutide.
- Installed prescriber base + 10+ years of real-world semaglutide safety data
- Kalundborg + Clayton (NC) capacity expansions to relieve supply-constrained Wegovy demand
- Foundation ownership = long-duration capital allocation, no LBO/activist overhang
- Oral semaglutide opens the non-injectable obesity market
- Cardio + renal + MASH label extensions widen reimbursable population
- $LLY Zepbound out-trials Wegovy on weight-loss magnitude in head-to-head SURMOUNT data; share donor risk
- CagriSema Phase 3 readout (REDEFINE) missed buyside efficacy bar - stock repriced -20%+ on the print
- US compounding pharmacy GLP-1 supply has eroded brand pricing; FDA shortage delisting only partial relief
- Patent cliff on semaglutide ~2031-2032 in major markets, biosimilar/generic risk
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for NVO - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.